Physician profile
Farshid Mirzaee
NPI 1194969436
$5,317.11
in general payments reported to CMS, 2019-2025
32 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $436 · 2021: $389 · 2022: $801 · 2023: $1,900 · 2024: $818 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138 · Travel and Lodging: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.99 |
| Travel and Lodging | $819.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $1,137.63 | 2023 | |
| Boston Scientific Corporation | $1,135.68 | 2019-2024 | |
| Abbott Laboratories | $501.65 | 2020-2025 | Proclaim, Eterna, Octrode |
| Teleflex LLC | $480.14 | 2023-2024 | Urolift |
| Rochester Medical Corporation | $218.26 | 2022 | |
| Intuitive Surgical, INC. | $171.10 | 2019-2024 | |
| Astellas Pharma US INC | $168.42 | 2019-2021 | |
| Mimedx Group, INC. | $150.00 | 2024 | |
| Neotract INC. | $149.99 | 2019 | |
| Telix Pharmaceuticals | $136.91 | 2023 | Illuccix |
| Coloplast Corp | $125.46 | 2022 | |
| Axonics, INC. | $121.22 | 2022-2023 | Axonics |
| Integra Lifesciences Corporation | $117.91 | 2022 | |
| Laborie Medical Technologies Corp. | $117.39 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.90 | 2020-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $77.08 | 2020-2021 | |
| Abbvie INC. | $67.40 | 2020-2024 | |
| Sumitomo Pharma America, INC. | $41.81 | 2024-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $40.40 | 2019-2021 | |
| Urogen Pharma, INC. | $37.89 | 2025 | |
| Dendreon Pharmaceuticals LLC | $35.00 | 2024 | Provenge |
| Olympus America INC. | $33.95 | 2024-2025 | Itind System |
| Urovant Sciences INC | $25.52 | 2022 | |
| Janssen Biotech, INC. | $21.28 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $20.08 | 2019 | |
| Endo Pharmaceuticals INC. | $19.88 | 2019 | |
| Agile Therapeutics, INC. | $18.77 | 2022 | |
| Antares Pharma, INC. | $17.70 | 2025 | Xyosted |
| Therapeuticsmd, INC. | $15.67 | 2019 | |
| Agiliti Surgical, INC. | $13.50 | 2019 | |
| Avion Pharmaceuticals | $12.52 | 2022 | |
| Urocure LLC | $1.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farshid Mirzaee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.